Research Grade Bemarituzumab

Summary

Catalog No.	DHD47901
Alternative Names	FPA144 ,FPA-144, FPA114-A, CAS: 1952272-74-0
Clone ID	Bemarituzumab
Host species	Humanized
Species reactivity	Human
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Concentration	1 mg/ml
Purity	>95% as determined by SDS-PAGE.
Clonality	Monoclonal
Isotype	IgG1-kappa
Applications	Research Grade Biosimilar
Target	K-sam, KSAM, CD332, Keratinocyte growth factor receptor, Fibroblast growth factor receptor 2, FGFR-2, FGFR2, KGFR, BEK
Purification	Protein A/G purified from cell culture supernatant.
Endotoxin level	Please contact with the lab for this information.
Expression system	Mammalian Cells
Accession	P21802

Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Note	For research use only. Not suitable for clinical or therapeutic use.

Description

Bemarituzumab (bema), a first-in-class humanized IgG1 monoclonal antibody, selectively binds to 2b Isoform of thefibroblast growth factor receptor (FGFR2b). Bemarituzumab (FPA144) is a first-in-class humanized immunoglobulin G1 monoclonal antibody specific to the splice-variant FGFR2b that inhibits binding of the ligands FGF7, FGF10, and FGF22. Specifically, bemarituzumab does not inhibit binding of FGF23, the ligand responsible for phosphate and vitamin D metabolism, thereby potentially avoiding the risk of hyperphosphatemia associated with pan-FGFR tyrosine kinase inhibitors. Bemarituzumab is also glycoengineered for increased affinity for the human Fc gamma RIIIA receptor expressed on natural killer cells, enabling enhanced antibody-dependent cellmediated cytotoxicity.

Data Image



SDS-PAGE

SDS PAGE for Bemarituzumab



SEC-HPLC

The purity of this product is >95% as determined by SEC-HPLC.